0001209191-22-051239.txt : 20220926
0001209191-22-051239.hdr.sgml : 20220926
20220926160937
ACCESSION NUMBER: 0001209191-22-051239
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20220922
FILED AS OF DATE: 20220926
DATE AS OF CHANGE: 20220926
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Topper James N
CENTRAL INDEX KEY: 0001341382
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39094
FILM NUMBER: 221265788
MAIL ADDRESS:
STREET 1: 550 HAMILTON AVENUE, SUITE 100
CITY: PALO ALTO
STATE: CA
ZIP: 94301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Phathom Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001783183
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 824151574
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CAMPUS DRIVE,
STREET 2: SUITE 102
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
BUSINESS PHONE: (877) 742-8466
MAIL ADDRESS:
STREET 1: 100 CAMPUS DRIVE,
STREET 2: SUITE 102
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-09-22
0
0001783183
Phathom Pharmaceuticals, Inc.
PHAT
0001341382
Topper James N
C/O PHATHOM PHARMACEUTICALS, INC.
100 CAMPUS DRIVE, SUITE 102
FLORHAM PARK,
NJ
07932
1
0
1
0
Stock Option (Right to Buy
10.02
2022-09-22
4
A
0
20000
0.00
A
2032-09-21
Common Stock
20000
20000
D
The stock option will vest with respect to one-third of the shares of common stock on September 22, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following two years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.
/s/ Larry Miller, Attorney-in-Fact for James Topper
2022-09-26
EX-24
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and
appoints each of (i) the Chief Executive Officer, who is currently Terrie
Curran, and (ii) the Chief Financial Officer, who is currently Molly Henderson,
and (iii) the General Counsel, who is currently Larry Miller, and their
respective successors, signing singly, the undersigned's true and lawful
attorney-in-fact to:
(1) prepare, execute in the undersigned's name and on the undersigned's
behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a
Form ID, including amendments thereto, and any other documents necessary or
appropriate to obtain codes and passwords enabling the undersigned to make
electronic filings with the SEC of reports required by Section 16(a) of the
Securities Exchange Act of 1934 or any rule or regulation of the SEC;
(2) execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer and/or director of Phathom Pharmaceuticals, Inc., a Delaware
corporation (the "Company") and/or beneficial owner of more than 10% of the
Company's capital stock, Forms 3, 4, and 5 and any amendments thereto in
accordance with Section 16(a) of the Securities Exchange Act of 1934 and the
rules thereunder;
(3) do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such Form 3, 4,
or 5, complete and execute any amendment or amendments thereto, and timely file
such form with the SEC and any stock exchange or similar authority; and
(4) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this Power of Attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934.
The undersigned agrees that each such attorney-in-fact herein may rely entirely
on information furnished orally or in writing by the undersigned to such
attorney-in-fact. The undersigned also agrees to indemnify and hold harmless
the Company and each such attorney-in-fact against any losses, claims, damages
or liabilities (or actions in these reports) that arise out of or are based upon
any untrue statements or omission of necessary facts in the information provided
by the undersigned to such attorney-in-fact for purposes of executing,
acknowledging, delivering or filing Forms 3, 4 or 5 (including amendments
thereto) or Form ID and agrees to reimburse the Company and such
attorney-in-fact for any legal or other expenses reasonably incurred in
connection with investigating or defending against any such loss, claim, damage,
liability or action.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 22nd day of September, 2022.
Signature: /s/ James Topper
Name: James Topper, M.D., Ph.D.